Advertisement
Australia markets closed
  • ALL ORDS

    8,208.60
    +42.20 (+0.52%)
     
  • AUD/USD

    0.6626
    -0.0020 (-0.30%)
     
  • ASX 200

    7,971.10
    +39.40 (+0.50%)
     
  • OIL

    79.95
    +0.17 (+0.21%)
     
  • GOLD

    2,406.00
    +11.30 (+0.47%)
     
  • Bitcoin AUD

    101,371.53
    -265.62 (-0.26%)
     
  • CMC Crypto 200

    1,383.63
    -1.63 (-0.12%)
     

Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.

Company Fireside Chat Presentation Details:

 

 

Date:

Wednesday, September 20, 2023

 

 

Time:

4:20 pm Eastern Time

 

 

Webcast:

Register here

 

 

Presenters:

Ian Mortimer, President and Chief Executive Officer
Sherry Aulin, Chief Financial Officer

 

 

A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

ADVERTISEMENT

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com